A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

Charlotte Jacobs, Gary Lyman, Enríque Velez-García, Kasi S. Sridhar, William Knight, Howard Hochster, Lawrence T. Goodnough, Joanne E. Mortimer, Lawrence Einhorn, Lee Schacter, Nehemiah Cherng, Traci Dalton, Jim Burroughs, Marcel Rozencweig

Research output: Contribution to journalArticle

479 Citations (Scopus)

Abstract

Purpose: To determine whether combination chemotherapy is superior to single agents for recurrent/ metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. Patients and Methods: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 × 4), CP, or 5-FU every 3 weeks. Results: The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recur- rence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. Conclusion: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number2
StatePublished - 1992
Externally publishedYes

Fingerprint

Fluorouracil
Cisplatin
Head and Neck Neoplasms
Survival
Alopecia
Combination Drug Therapy
Carcinoma, squamous cell of head and neck
Histology
Multivariate Analysis
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jacobs, C., Lyman, G., Velez-García, E., Sridhar, K. S., Knight, W., Hochster, H., ... Rozencweig, M. (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 10(2), 257-263.

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. / Jacobs, Charlotte; Lyman, Gary; Velez-García, Enríque; Sridhar, Kasi S.; Knight, William; Hochster, Howard; Goodnough, Lawrence T.; Mortimer, Joanne E.; Einhorn, Lawrence; Schacter, Lee; Cherng, Nehemiah; Dalton, Traci; Burroughs, Jim; Rozencweig, Marcel.

In: Journal of Clinical Oncology, Vol. 10, No. 2, 1992, p. 257-263.

Research output: Contribution to journalArticle

Jacobs, C, Lyman, G, Velez-García, E, Sridhar, KS, Knight, W, Hochster, H, Goodnough, LT, Mortimer, JE, Einhorn, L, Schacter, L, Cherng, N, Dalton, T, Burroughs, J & Rozencweig, M 1992, 'A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck', Journal of Clinical Oncology, vol. 10, no. 2, pp. 257-263.
Jacobs, Charlotte ; Lyman, Gary ; Velez-García, Enríque ; Sridhar, Kasi S. ; Knight, William ; Hochster, Howard ; Goodnough, Lawrence T. ; Mortimer, Joanne E. ; Einhorn, Lawrence ; Schacter, Lee ; Cherng, Nehemiah ; Dalton, Traci ; Burroughs, Jim ; Rozencweig, Marcel. / A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 2. pp. 257-263.
@article{4fad1bce90034173bd4ef594382eabb0,
title = "A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck",
abstract = "Purpose: To determine whether combination chemotherapy is superior to single agents for recurrent/ metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. Patients and Methods: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 × 4), CP, or 5-FU every 3 weeks. Results: The overall response rate to the combination (32{\%}) was superior to that of CP (17{\%}) or 5-FU (13{\%}) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recur- rence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. Conclusion: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.",
author = "Charlotte Jacobs and Gary Lyman and Enr{\'i}que Velez-Garc{\'i}a and Sridhar, {Kasi S.} and William Knight and Howard Hochster and Goodnough, {Lawrence T.} and Mortimer, {Joanne E.} and Lawrence Einhorn and Lee Schacter and Nehemiah Cherng and Traci Dalton and Jim Burroughs and Marcel Rozencweig",
year = "1992",
language = "English (US)",
volume = "10",
pages = "257--263",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

AU - Jacobs, Charlotte

AU - Lyman, Gary

AU - Velez-García, Enríque

AU - Sridhar, Kasi S.

AU - Knight, William

AU - Hochster, Howard

AU - Goodnough, Lawrence T.

AU - Mortimer, Joanne E.

AU - Einhorn, Lawrence

AU - Schacter, Lee

AU - Cherng, Nehemiah

AU - Dalton, Traci

AU - Burroughs, Jim

AU - Rozencweig, Marcel

PY - 1992

Y1 - 1992

N2 - Purpose: To determine whether combination chemotherapy is superior to single agents for recurrent/ metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. Patients and Methods: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 × 4), CP, or 5-FU every 3 weeks. Results: The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recur- rence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. Conclusion: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.

AB - Purpose: To determine whether combination chemotherapy is superior to single agents for recurrent/ metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. Patients and Methods: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 × 4), CP, or 5-FU every 3 weeks. Results: The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recur- rence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. Conclusion: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.

UR - http://www.scopus.com/inward/record.url?scp=0026569931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026569931&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 257

EP - 263

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -